Dr. Anita Kumar, MD

Dr. Kumar practices at Memorial Sloan Kettering Basking Ridge in Basking Ridge, New Jersey.

Dr. Kumar's NPI, 1144489295, was assigned on June 4, 2008. Dr. Kumar graduated from Feinberg School of Medicine in 2008. Dr. Kumar holds New York license 261104.

Dr. Kumar's primary practice is Memorial Sloan Kettering Basking Ridge, at 136 Mountainview Blvd, Basking Ridge, NJ 07920 in Somerset County. The practice phone is (908) 542-3000.

Dr. Kumar's primary practice is Memorial Sloan Kettering Basking Ridge in Basking Ridge, New Jersey. Dr. Kumar is also affiliated with Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey. Dmand AI also links Dr. Kumar to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kumar practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kumar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kumar is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kumar's licenses on file in 5 states: New York, Florida, Pennsylvania, New Jersey and Massachusetts.

Dmand AI lists breast cancer, chronic leukemia, lung cancer, lymphoma and prostate cancer among the conditions Dr. Kumar treats.

CMS data shows 858 Medicare services from Dr. Kumar across 7 procedure codes in 2024, for 316 Medicare patients. Medicare paid $80,150 for them.

CMS counts 316 Medicare patients who saw Dr. Kumar in 2024. The largest group is 65 to 74, with 140 patients. 74% of them have high cholesterol, and 68% have high blood pressure. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kumar's median patient age at 73, with 49% women.

In 2024, Dr. Kumar wrote 691 Medicare Part D claims for 109 patients. 76% of them were for generic drugs. CMS names the drug for 564 of them, across 11 drugs with 11 or more claims each, at $1,671,277 in total drug cost. In 2023, CMS named 455 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Kumar for performance year 2024, reported as part of a group. Dr. Kumar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kumar as offering telehealth.

Dmand AI links 109 papers to Dr. Kumar, published from 2011 to 2025. 2021 was the busiest year, with 20. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Mantle-Cell and Hodgkin Disease. Dr. Kumar has published most often in Blood Adv. Dr. Kumar's most frequent co-authors are Anita J. Kumar, MD, Paul A. Hamlin, MD and Matthew J. Matasar, MD.

Dmand AI links Dr. Kumar to 9 clinical trials, 2 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin and Lymphoma, B-Cell. Memorial Sloan Kettering Cancer Center sponsors the most, 7.

CMS Open Payments shows 43 general payments to Dr. Kumar from 11 drug and device companies from 2020 to 2025. Consulting fees make up the largest share, 98% of the total. AstraZeneca Pharmaceuticals LP paid the most, $26,424. It also lists 1 research payment totaling $576 in 2024.

Dr. Kumar graduated from Feinberg School of Medicine in 2008.

Dr. Kumar is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.